• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    EVP & Chief Risk Officer Paiano Robert W sold $1,539,714 worth of shares (13,138 units at $117.20) and exercised 13,138 shares at a strike of $43.59 (SEC Form 4)

    3/13/25 4:09:48 PM ET
    $HIG
    Property-Casualty Insurers
    Finance
    Get the next $HIG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Paiano Robert W

    (Last) (First) (Middle)
    ONE HARTFORD PLAZA

    (Street)
    HARTFORD CT 06155

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HARTFORD INSURANCE GROUP, INC. [ HIG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP & Chief Risk Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/11/2025 M 13,138 A $43.59 44,815.621 D
    Common Stock 03/11/2025 S 13,138 D $117.1955(1) 31,677.621 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $43.59 03/11/2025 M 13,138 (2) 03/01/2026 Common Stock 13,138 $0.0000 0.0000 D
    Stock Option $48.89 (3) 02/28/2027 Common Stock 13,934 13,934 D
    Stock Option $49.01 (4) 02/26/2029 Common Stock 34,159 34,159 D
    Stock Option $51.87 (5) 02/23/2031 Common Stock 30,242 30,242 D
    Stock Option $53.81 (6) 02/27/2028 Common Stock 26,702 26,702 D
    Stock Option $55.27 (7) 02/25/2030 Common Stock 30,840 30,840 D
    Stock Option $69.41 (8) 02/23/2032 Common Stock 27,174 27,174 D
    Stock Option $78.28 (9) 02/28/2033 Common Stock 21,337 21,337 D
    Stock Option $95.74 (10) 02/27/2034 Common Stock 8,731 8,731 D
    Stock Option $116.41 (11) 02/25/2035 Common Stock 8,010 8,010 D
    Explanation of Responses:
    1. Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $117.14 - $117.26 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
    2. The options became fully exercisable on March 1, 2019, the third anniversary of the grant date.
    3. The options became fully exercisable on February 28, 2020, the third anniversary of the grant date.
    4. The options became fully exercisable on February 26, 2022, the third anniversary of the grant date.
    5. The options became fully exercisable on February 23, 2024, the third anniversary of the grant date.
    6. The options became fully exercisable on February 27, 2021, the third anniversary of the grant date.
    7. The options became fully exercisable on February 25, 2023, the third anniversary of the grant date.
    8. The options became fully exercisable on February 23, 2025, the third anniversary of the grant date.
    9. One-third of the options became exercisable on February 28, 2024, an additional one-third of the options became exercisable on February 28, 2025 and the remaining one-third of the options will become exercisable on February 28, 2026, the third anniversary of the grant date.
    10. One-third of the options became exercisable on February 27, 2025, an additional one-third of the options will become exercisable on February 27, 2026 and the remaining one-third of the options will become exercisable on February 27, 2027, the third anniversary of the grant date.
    11. One-third of the options will become exercisable on February 25, 2026, an additional one-third of the options will become exercisable on February 25, 2027 and the remaining one-third of the options will become exercisable on February 25, 2028, the third anniversary of the grant date.
    Anthony J. Salerno, Jr., Attorney-in-Fact 03/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HIG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HIG

    DatePrice TargetRatingAnalyst
    1/6/2025$130.00 → $135.00Equal Weight → Overweight
    Barclays
    10/4/2024$113.00 → $121.00Buy → Neutral
    BofA Securities
    9/5/2024$130.00Equal Weight
    Barclays
    6/28/2024$116.00 → $114.00Buy → Neutral
    Citigroup
    1/10/2024$132.00Outperform
    TD Cowen
    1/8/2024$94.00 → $91.00Overweight → Neutral
    JP Morgan
    11/16/2023Perform
    Oppenheimer
    10/5/2023$85.00Hold
    Deutsche Bank
    More analyst ratings